Are you locked in a traditional product marketing mind set? Time to move on... How can you provide better support and awareness to HCPs and patients for your brands? Content marketing may be the answer. Advocates argue...

The biologics competitive landscape is at a critical stage of development. How will you respond? Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete...

How is technology changing the face of MSL/KOL interaction and which technologies are set to take a greater role is this critical relationship? Which technologies are being employed to identify KOLs? What technology...

So what will persuade US payers to better support orphan drugs? US payer concern at the number of new orphan drugs coming to market, often with eye watering prices attached, can obscure a more positive message: payers...

Explore the latest payer views and requirements for pay for performance When it comes to payment for performance (P4P), it's notoriously difficult to know exactly what payers want to see. Useful face-to-face payer...

Which market access teams will be first to unlock the power of patient journey mapping? There's no doubt that market access has evolved significantly in recent years, but there is so much more to be done. What some...

Biosimilars: Evaluating opportunities and risks in emerging markets Are you seeking new opportunities for biosimilars? The potential in emerging markets remains attractive, however the high-profile BRIC countries - and...

Benchmark your payer engagement team's performance against the industry's best! Winning payer support to secure reimbursement and optimum pricing is a battle payer engagement teams' face daily. But in the face of ever...